A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants
Status:
Completed
Trial end date:
2018-09-14
Target enrollment:
Participant gender:
Summary
This single-arm, open-label, local multicenter study will evaluate the safety and
tolerability of trastuzumab administered subcutaneously (SC) by a single-use injection device
(SID) in participants with human epidermal growth factor receptor 2 (HER2)-positive early
breast cancer (EBC), following surgery and chemotherapy (neo-adjuvant or adjuvant).